HC Wainwright Has Bullish Outlook for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Research analysts at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $0.64 per share for the year, up from their prior forecast of $0.63. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.51) per share.

Other equities analysts have also issued reports about the company. StockNews.com raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Barclays boosted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday.

Sangamo Therapeutics Stock Down 11.9 %

Shares of SGMO opened at $2.15 on Friday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $0.85.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Sangamo Therapeutics during the first quarter worth $331,000. State Board of Administration of Florida Retirement System lifted its holdings in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the period. Finally, Marshall Wace LLP grew its stake in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.